Physician profile
Steve E Vacalis
NPI 1871580399
$692,581.90
in general payments reported to CMS, 2019-2025
31 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175K · 2020: $114K · 2021: $140K · 2022: $129K · 2023: $55K · 2024: $27K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $25K · Travel and Lodging: $7,819 · Food and Beverage: $5,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,992.44 |
| Consulting Fee | $24,650.50 |
| Travel and Lodging | $7,819.45 |
| Food and Beverage | $5,519.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $413,645.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $87,349.32 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $84,786.26 | 2019-2024 | Xarelto |
| Allergan, INC. | $44,088.54 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $21,692.59 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13,804.96 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $9,114.53 | 2019 | |
| Daiichi Sankyo INC. | $6,276.97 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $3,719.68 | 2022-2023 | Seglentis |
| Xeris Pharmaceuticals, INC. | $3,054.36 | 2020-2021 | |
| Abbott Laboratories | $2,044.74 | 2022-2025 | Afinion 2, Freestyle Libre 3 |
| Janssen Scientific Affairs, LLC | $1,372.57 | 2019-2021 | |
| Pfizer INC. | $504.11 | 2022-2025 | |
| Paratek Pharmaceuticals, INC. | $249.08 | 2021-2023 | Nuzyra |
| Forte Bio-Pharma LLC | $211.52 | 2019-2025 | Prolate, Tanlor, Nalocet |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $112.95 | 2024 | Cologuard Collection Kit |
| Viiv Healthcare Company | $95.57 | 2022-2023 | Apretude |
| Antares Pharma, INC. | $90.32 | 2024-2025 | Xyosted |
| Sanofi-Aventis U.S. LLC | $73.71 | 2022 | |
| Spr Therapeutics, INC | $47.86 | 2025 | Sprint Pns System |
| Dexcom, INC. | $36.81 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $33.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $32.65 | 2021-2024 | Shingrix, Arexvy |
| Amgen INC. | $32.14 | 2021-2025 | Otezla, Repatha |
| Halozyme INC | $23.90 | 2023 | |
| Verity Pharmaceuticals INC. | $17.83 | 2025 | Tlando |
| Cequr Corporation | $16.75 | 2023 | Cequr Simplicity |
| Duchesnay USA Incorporated | $16.64 | 2019 | |
| Horizon Therapeutics Plc | $12.94 | 2019 | |
| Merck Sharp & Dohme LLC | $11.89 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Vacalis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.